Subject: Selpercatinib for Lung Cancer with RET Alterations - Cancer Currents Blog
From: National Cancer Institute <[email-masked]>
To: [email-masked]
Date: Fri, 27 Sep 2019 14:33:45 +0000

Having trouble viewing this email? View it as a Web page.

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.

Selpercatinib Shows Promise against Lung Cancers with Alterations in RET Gene

09/27/2019

The investigational drug selpercatinib may benefit patients with lung cancer whose tumors have alterations in the RET gene, including fusions with other genes, according to results from a small clinical trial.

Stay Connected with the National Cancer Institute

Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237)

SUBSCRIBER SERVICES:
Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to [email-masked] using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892